JP2020522269A - レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター - Google Patents

レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター Download PDF

Info

Publication number
JP2020522269A
JP2020522269A JP2019567677A JP2019567677A JP2020522269A JP 2020522269 A JP2020522269 A JP 2020522269A JP 2019567677 A JP2019567677 A JP 2019567677A JP 2019567677 A JP2019567677 A JP 2019567677A JP 2020522269 A JP2020522269 A JP 2020522269A
Authority
JP
Japan
Prior art keywords
mir
hsa
mirna
nucleic acid
mecp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522269A5 (OSRAM
Inventor
エステベス，ミゲル，セナ
ガオ，グワンピン
グリーン，マイケル，アール．
ワン，ダン
シモーヌ，テサ，メルセデス
Original Assignee
ユニバーシティ オブ マサチューセッツ
ユニバーシティ オブ マサチューセッツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ マサチューセッツ, ユニバーシティ オブ マサチューセッツ filed Critical ユニバーシティ オブ マサチューセッツ
Publication of JP2020522269A publication Critical patent/JP2020522269A/ja
Publication of JP2020522269A5 publication Critical patent/JP2020522269A5/ja
Priority to JP2023135189A priority Critical patent/JP2023164447A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019567677A 2017-06-06 2018-06-06 レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター Pending JP2020522269A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023135189A JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516060P 2017-06-06 2017-06-06
US62/516,060 2017-06-06
PCT/US2018/036200 WO2018226785A1 (en) 2017-06-06 2018-06-06 Self-regulating aav vectors for safe expression of mecp2 in rett syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135189A Division JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター

Publications (2)

Publication Number Publication Date
JP2020522269A true JP2020522269A (ja) 2020-07-30
JP2020522269A5 JP2020522269A5 (OSRAM) 2021-07-26

Family

ID=64567243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567677A Pending JP2020522269A (ja) 2017-06-06 2018-06-06 レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるｍｅｃｐ２の安全な発現のための自己調節ａａｖベクター

Country Status (15)

Country Link
US (2) US11680275B2 (OSRAM)
EP (1) EP3635122A4 (OSRAM)
JP (2) JP2020522269A (OSRAM)
KR (1) KR20200015701A (OSRAM)
CN (1) CN111065742A (OSRAM)
AU (1) AU2018281145A1 (OSRAM)
BR (1) BR112019025732A2 (OSRAM)
CA (1) CA3066623A1 (OSRAM)
CL (1) CL2019003582A1 (OSRAM)
CO (1) CO2019014840A2 (OSRAM)
EA (1) EA201992882A1 (OSRAM)
IL (1) IL271170A (OSRAM)
MX (1) MX2019014760A (OSRAM)
SG (1) SG11201911737PA (OSRAM)
WO (1) WO2018226785A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542614A (ja) * 2020-08-19 2023-10-11 サレプタ セラピューティクス， インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
CA3044291A1 (en) 2016-11-17 2018-05-24 Nationwide Children's Hospital Inc. Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
US12138298B2 (en) 2017-01-30 2024-11-12 Brainvectis Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
EP3773743A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
AU2019354995B2 (en) 2018-10-02 2024-12-12 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
US20220202960A1 (en) * 2019-04-24 2022-06-30 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
JP7624410B2 (ja) * 2019-05-21 2025-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル レット症候群の治療におけるコレステロール ２４－ヒドロラーゼのための発現ベクター
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
WO2021113634A1 (en) * 2019-12-05 2021-06-10 The Board Of Regents Of The University Of Texas Transgene cassettes designed to express a human mecp2 gene
WO2021183433A1 (en) * 2020-03-09 2021-09-16 University Of Massachusetts Gene replacement therapy for foxg1 syndrome
US20230203102A1 (en) * 2020-05-13 2023-06-29 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
EP4172330A1 (en) * 2020-06-30 2023-05-03 The University Court Of The University of Edinburgh Transgene expression system
CN112194706B (zh) * 2020-09-30 2022-03-08 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
KR20240113624A (ko) 2021-11-02 2024-07-22 보이저 테라퓨틱스, 인크. Aav 캡시드 변이체 및 이의 용도
GB202201242D0 (en) * 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
WO2024194491A1 (en) * 2023-03-22 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
WO2024235164A1 (zh) * 2023-05-15 2024-11-21 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗
TW202513796A (zh) * 2023-06-09 2025-04-01 大陸商仁景（蘇州）生物科技有限公司 表達可調控的工程化ｒｎａ分子及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501760A (ja) * 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
JP2011510021A (ja) * 2008-01-17 2011-03-31 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
JP2013540789A (ja) * 2010-10-25 2013-11-07 ユニヴェルシテ デクス−マルセイユ Ｍｅｃｐ２関連障害の処置

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2915124C (en) 2001-11-13 2018-08-14 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20040106566A1 (en) 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
US20160000794A1 (en) 2012-09-25 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods for the diagnosis and treatment of sjogren's syndrome
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
US10975391B2 (en) * 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
RU2020140209A (ru) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
WO2016172008A1 (en) 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
EP3121284A1 (en) 2015-07-22 2017-01-25 Ecole Polytechnique Fédérale de Lausanne (EPFL) Bicistronic aav vector for rna interference in als

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501760A (ja) * 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
JP2011510021A (ja) * 2008-01-17 2011-03-31 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
JP2013540789A (ja) * 2010-10-25 2013-11-07 ユニヴェルシテ デクス−マルセイユ Ｍｅｃｐ２関連障害の処置

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOLECULAR MEDICINE REPORTS, 2015, VOL.12, PP.5399-5406, JPN6023001652, ISSN: 0005127716 *
MOLECULAR THERAPY, 2011, VOL.19, NO.3, PP.526-535, JPN6022013133, ISSN: 0005127715 *
MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, 2017, VOL.5, PP.106-115, PUBLISHED MAY 02, 2017, JPN6022013137, ISSN: 0005127713 *
MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, 2017, VOL.5, PP.180-190, PUBLISHED MAY 05, 2017, JPN6022013135, ISSN: 0005127714 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542614A (ja) * 2020-08-19 2023-10-11 サレプタ セラピューティクス， インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター

Also Published As

Publication number Publication date
US20230416779A1 (en) 2023-12-28
BR112019025732A2 (pt) 2020-06-30
IL271170A (en) 2020-01-30
EP3635122A1 (en) 2020-04-15
KR20200015701A (ko) 2020-02-12
SG11201911737PA (en) 2020-01-30
CN111065742A (zh) 2020-04-24
US11680275B2 (en) 2023-06-20
JP2023164447A (ja) 2023-11-10
EP3635122A4 (en) 2021-03-31
AU2018281145A1 (en) 2020-01-02
US20200181646A1 (en) 2020-06-11
WO2018226785A1 (en) 2018-12-13
CL2019003582A1 (es) 2020-09-25
CA3066623A1 (en) 2019-12-13
MX2019014760A (es) 2020-08-03
EA201992882A1 (ru) 2020-05-25
CO2019014840A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
US20230416779A1 (en) Self-regulating aav vectors for safe expression of mecp2 in rett syndrome
US20240139340A1 (en) Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
US12054715B2 (en) Modified AAV constructs and uses thereof
US10894949B2 (en) Recombinant AAVS having useful transcytosis properties
CN115698039A (zh) 衣壳变体及其用途
US20240414062A9 (en) Use of inverted terminal repeats (itrs) from adeno-associated virus serotypes 8 and rh.39 in gene therapy vectors
US20230089312A1 (en) Inducible single aav system and uses thereof
US12391947B2 (en) Modulation of SPTLC1 via recombinant adeno-associated vectors
US20230348914A1 (en) Compositions and methods for treatment of acute liver failure
US20250320256A1 (en) Aav5 capsid with non-canonical amino acid incorporation and uses thereof
US20240207441A1 (en) Capsid variants and uses thereof
US20250387511A1 (en) Aav2 variants and uses thereof
US20250319207A1 (en) Capsid variants and uses thereof
EA045780B1 (ru) САМОРЕГУЛИРУЕМЫЕ ВЕКТОРЫ НА ОСНОВЕ AAV ДЛЯ БЕЗОПАСНОЙ ЭКСПРЕССИИ MeCP2 ПРИ СИНДРОМЕ PETTA
WO2024216032A1 (en) Compositions and methods for treatment of acute liver failure
WO2025212884A1 (en) Discovery of novel aav capsid proteins through directed evolution of the vp1u region
WO2024220389A2 (en) Aav2 variants and uses thereof
WO2024220461A2 (en) Aav capsid proteins having mutations in the vp1 region

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230814